SPECIAL NOTICE

We are working on upgrading our websites and despite our best endeavours have experienced census type calamities for almost a week now. Our apologies, we hope to have all problems resolved by Monday August 15th.

SEARCH BY NAME

BROWSE

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH BY CODE

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

ESENSE-LAB LTD(ESE)

SHARE PRICES

(updated at weekends)

Former (or subsequent) names

 

Shareholder links

Our website ranking of ESE: rating 5
(5 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Link Market Services, Level 12 QV1 Building 250 St Georges Terrace Perth WA 6000

Tel : +61 8 9211 6670 or 1300 554 474
Fax : +61 2 9287 0303
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000ESE9
Address: Suite 6, 295 Rokeby Road Subiaco, Western Australia 6008
Tel:  +61 8 6555 2950 Fax: +61 8 6166 0261

Date first listed: 14/02/2017
Company Secretary: Erlyn Dale, Winton Willesee
Sector: Pharmaceuticals, Biotechnology & Life Sciences Industry Group: 
Activities: Technology and research and development in the creation of virtual plants

News & Events

Expand this box to read and print

OFX Transferring Money Internationally to Free

The company lodges its Appendix 4D and Half Year Accounts.

01/09/2020

eSense has signed a research agreement with the Israeli Ministry of Health to commence a joint research project at the Central Virology lab located in the Chaim Sheba Medical Centre, the largest hospital in Israel, to test its proprietary TRP-ENVTM compound. The aim of the research project is to test TRP-ENV's efficacy against human coronavirusstrain termed OC43, that will be used as a model for SARS COV2, and will provide further research into terpenes' anti-viral qualities to reduce the ethanol content in sanitisers. Results will be relevant to previously announced projects with Wise Wine and SeaLaria. Tests will be conducted in stages with final results expected by November 2020. Approval for eSense to conduct these tests was granted by the MOH following several months of discussion with the Israeli central virologly lab of the MOH.

31/08/2020

The company has become aware, following ASX queries, that it has not been in compliance with. In relation to Article 34 of the Articles of Association, the Company is pleased to confirm that the Company's joint company secretary, Mr Winton Willesee, has agreed to be appointed as an interim non-executive director of the Company, effective immediately. In relation to the Company not having the required number of "˜External Directors', the Companies Law requires the Company call a shareholders' meeting as soon as possible to appoint replacement External Directors. The Company intends to call a shareholders' meeting as soon as possible to consider the appointment of 2 new External Directors. ASX will require the Company's securities to remain in suspension until the conditions mentioned above are satisfied. The Company is also advancing its commercialisation efforts and accelerating the current business plan.

31/07/2020

The company lodges its Quarterly Activities Report and Appendix 4C.

31/07/2020

The securities of eSense-Lab Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of ESE, pending the release of an announcement regarding ASX's queries in relation to ESE's board composition and an announcement regarding a research agreement.

27/07/2020

The suspension of trading in the securities of eSense-Lab Ltd will be lifted immediately following the release by ESE of an announcement regarding capital raising.

14/04/2020

The company completes $1.145 million capital raising. $250,000 in Loan Notes issued to Sophisitcated Investors. Secures firm commitments from Sophisitcated Investors for a placement of securities to raise an additional $895,000 (conditional on shareholder approval).

14/04/2020

The voluntary suspension is to last until the earlier of the company releasing an announcement regarding the capital raising or prior to commencement of trading on Tuesday, 14 April 2020.

09/04/2020

The securities of eSense-Lab Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of ESE, pending the release of an announcement regarding a capital raising.

07/04/2020

The suspension of trading in the securities of eSense-Lab Ltd will be lifted from the commencement of trading on Thursday, 3 May 2018, following release of the Company's quarterly reports and receipt of satisfactory responses to ASX queries.

02/05/2018

The company lodges its Quarterly Activities & Appendix 4C Cashflow Report.

30/04/2018

The company releases its Appendix 4G and Corporate Governance Statement.

04/04/2018

MMJ PhytoTech Limited notes that the shareholders of e-Sense Lab have not approved the issuance to MMJ of free options to acquire 1.25 million ordinary shares of e-Sense at $0.30 per share. Accordingly, under the terms of the placement of 2.5 million ordinary shares to MMJ by e-Sense in November 2017, e-Sense is to pay $199,000 to MMJ in consideration for those unapproved options.

03/04/2018

The company releases the results of its AGM and EGM.

03/04/2018

The company lodges its Full Year Statutory Accounts.

29/03/2018

The company releases the Chairman's Address to Shareholders.

29/03/2018

The company issues a response to ASX query.

29/03/2018

The company issues a response to ASX Query.

28/03/2018

The securities of eSense-Lab Limited will be suspended from official quotation immediately pursuant to Listing Rule 17.3.

23/03/2018

listed entity carried for record purposes only

14/02/2017

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...

     


    Directors' on-market share transactions (last 5)

     

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    James EllingfordNon Exec Chairman13/01/2020
    Itzik MizrahiCEO09/03/2020
    Peter HatfullNon Exec Director02/07/2020
    Winton WilleseeNon Exec Director31/07/2020
    Haim CohenDirector14/02/2017
    Benjamin KarasikDirector09/02/2018

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Piers LewisNon Exec Director30/11/201802/07/2020
    Amit EdrNon Exec Director30/11/201809/06/2020
    Michael EdwardsNon Exec Director08/11/201927/03/2020
    Galit AsafNon Exec Director14/02/201708/11/2019
    Kobi ZechariaNon Exec Director30/05/201820/12/2018
    Ilan SaadChairman14/02/201711/05/2018
    Eran GilboaNon Exec Director14/02/201711/05/2018
    Quentin MegsonNon Exec Director14/02/201729/03/2018
    Brendan de KauweDirector14/02/201729/03/2018

    Date of first appointment, title may have changed.